

Dr Darryl Maher Joins Cynata Board

Melbourne, Australia; 16 June 2020: Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the appointment of Dr Darryl Maher as an independent Non-Executive Director effective 16 June 2020, and advises that Mr Peter Webse will step down from his position on the Board.

Key Highlights

- **Dr Darryl Maher, former senior R&D Executive at CSL, brings significant global development expertise to the Cynata Board of Directors**
- **Mr Peter Webse to step down after 8 years on Cynata Board**

Dr Maher said, *“I am delighted to be joining Cynata at a time when the Company has such an exciting Phase 2 clinical pipeline founded on successful pre-clinical and early clinical product development. Cynata has recognised the major challenge in commercialising sophisticated therapeutic products and its proprietary Cymerus™ technology addresses that challenge through a robust and economic mesenchymal stem cell manufacturing platform. As the leading company in the world at the cutting edge of induced pluripotent stem cell (iPSC) production systems, I am very pleased to be involved in the next stage of the Company’s growth.”*

Dr Maher adds global biopharmaceutical development and commercialisation capability to the Cynata board, with over 23 years’ experience with CSL Limited. CSL is one of the world’s most successful developers of biologic pharmaceutical products and has a market capitalisation of ~A\$130 billion.

Dr Maher has had a long and successful career in pharmaceutical product development, most recently as the former Vice President of R&D and Medical Affairs at CSL Behring Australia where he was responsible for the development of multiple successful drug products from initiation through clinical development and ultimately to commercialisation. Dr Maher undertook medical training, qualified as a specialist haematologist and completed a PhD before commencing his career in the pharmaceutical industry.

In addition, Mr Peter Webse, who has been a Non-Executive Director of Cynata since 2012, will step down from the Board effective 30 June 2020. The Company extends warm thanks and appreciation to Peter for his role in building the Company from its IPO to the enterprise it is today. Peter will continue to remain Company Secretary, a position which he has also held since 2012.

Cynata Therapeutics Chairman, Dr Paul Wotton, said, *“Cynata continues to build a leading team with the addition of Dr Maher. With our rich and diverse Phase 2 product pipeline progressing, Darryl’s experience in global biopharmaceutical development and commercialisation will be a valuable addition. We welcome Darryl to the Board and look forward to his contributions toward the advancement of Cynata and the Cymerus product pipeline. We also thank Peter Webse for his years of contribution to Cynata as a Non-Executive Director.”*

-ENDS-

Authorised for release by the Board

CONTACTS: Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119343, ross.macdonald@cynata.com
Claire LaCagnina, U.S. Media Contact, +1 315.765.1462, clacagnina@6degreespr.com



About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus, a proprietary therapeutic stem cell platform technology. Cymerus overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynata's lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Cynata plans to advance its Cymerus MSCs into Phase 2 trials for GvHD, critical limb ischemia and osteoarthritis. In addition, Cynata has demonstrated utility of its Cymerus MSC technology in preclinical models of asthma, diabetic wounds, sepsis, heart attack and cytokine release syndrome, a life-threatening condition stemming from cancer immunotherapy.

Cynata Therapeutics Limited

Level 3, 62 Lygon Street, Carlton, Victoria 3053, Australia
PO Box 7165, Hawthorn North, Victoria 3122
T: + 613 9824 5254 F: + 613 9822 7735 E: info@cynata.com
ABN - 98 104 037 372